logo-loader
viewFutura Medical PLC

Futura Medical starts work on Phase III trial for its erectile dysfunction gel

The AIM-listed firm said the trial will be a dose ranging, multicentre, randomised, double blind, placebo controlled, home use, parallel group clinical trial of topically applied glyceryl trinitrate (GNT)

laboratory
Futura said this study will recruit approximately 1,000 patients with mild, moderate and severe ED

Futura Medical PLC (LON:FUM) has commenced preparatory work on the first Phase III efficacy trial for MED2002, the company’s topical gel for erectile dysfunction (ED).

The AIM-listed firm said this trial will be a dose ranging, multicentre, randomised, double-blind, placebo-controlled, home use, parallel group clinical trial of topically applied glyceryl trinitrate (GNT).

WATCH: Futura Medical kicks off work on Phase III trial for erectile dysfunction gel

The healthcare company said the study will recruit approximately 1,000 patients with mild, moderate and severe ED and compare the efficacy of 0.2%, 0.4% and 0.6% GTN doses of MED2002 against that of the placebo.

The trial will be conducted throughout Eastern Europe with a three-month study period for each patient.

Futura said it is confident that the positive pharmacokinetic data published this month supports the decision to conduct Phase III studies at higher doses than previously studied, with 0.6% GTN the maximum dose that would likely be considered suitable for the 505(b)(2) regulatory pathway in the USA. 

Depending on the speed of regulatory approval and patient recruitment proceeding, Futura expects the first patient to be dosed by the end of September 2018, and headline efficacy results to be announced by the end of December 2019.

James Barder, chief executive of Futura Medical, said: “The potential for MED2002 as a safe, rapid and effective treatment for erectile dysfunction is huge. We are pleased to report that discussions regarding commercialisation are progressing and we look forward to providing shareholders with a further update at the appropriate time.”

Quick facts: Futura Medical PLC

Price: 34.2 GBX

AIM:FUM
Market: AIM
Market Cap: £69.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Futura Medical kicks off work on Phase III trial for erectile dysfunction gel

James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive they've begun preparatory work on the first Phase III efficacy trial for MED2002 - their topical gel for erectile dysfunction (ED). The study will recruit approximately 1,000 patients with mild, moderate and...

on 27/4/18

2 min read